Erratum (DOI:10.1016/j.cancergencyto.2007.11.011);8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality

Cancer Genetics and Cytogenetics

Volumn 181, Issue 2, 2008, Pages 93-99

  Park, Tae Sung ^a   Song, Jaewoo ^a   Kim, Jin Seok ^a   Yang, Woo Ick ^a   Song, Sungwook ^a   Kim, Sue Jung ^a   Suh, Borum ^a   Choi, Jong Rak ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IFOSFAMIDE; METHOTREXATE; PROTEIN DERIVATIVE;

ADULT; ARTICLE; BIOPSY; CASE REPORT; CHROMOSOME 8P; CHROMOSOME TRANSLOCATION; COMBINATION CHEMOTHERAPY; CYTOGENETICS; FLOW CYTOMETRY; GENE FUSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME; KARYOTYPING; MALE; MYELOPROLIFERATIVE DISORDER; NASOPHARYNX TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LYMPHOMA;

EID: 39449120487     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.03.001     Document Type: Erratum

References (19)

1. Gotlib J., Cross N.C., and Gilliland D.G. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol 19 (2006) 535-569
2. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 114 (2005) 7-25
3. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia (2007) (Sept. 20; Epub ahead of print)
4. Cross N.C.P., and Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 16 (2002) 1207-1212
5. Macdonald D., Reiter A., and Cross N.C.P. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107 (2002) 101-107
6. Inhorn R.C., Aster J.C., Roach S.A., Slapak C.A., Soiffer R., Tantravahi R., and Stone R.M. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 85 (1995) 1881-1887
7. ISCN 2005: an international system for human cytogenetic nomenclature (2005). In: Shaffer L.G., and Tommerup N. (Eds) (2005), S. Karger, Basel
8. Guasch G., Mack G.J., Popovici C., Dastugue N., Birnbaum D., Rattner J.B., and Pébusque M.J. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 95 (2000) 1788-1796
9. Yamamoto K., Kawano H., Nishikawa S., Yakushijin K., Okamura A., and Matsui T. A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene. Eur J Haematol 77 (2006) 349-354
10. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours (2001), IARC Press, Lyon
11. Friedhoff F., Rajendra B., Moody R., and Alapatt T. Novel reciprocal translocation between chromosomes 8 and 9 found in a patient with myeloproliferative disorder. Cancer Genet Cytogenet 9 (1983) 391-394
12. Lewis J.P., Jenks H., and Lazerson J. Philadelphia chromosome-negative chronic myelogenous leukemia in a child with t(8;9)(p11 or 12;q34). Am J Pediatr Hematol Oncol 5 (1983) 265-269
13. Oscier D.G., Mufti G.J., Gardiner A., and Hamblin T.J. Reciprocal translocation between chromosomes 8 and 9 in atypical chronic myeloid leukemia. J Med Genet 22 (1985) 398-401
14. Jotterand Bellomo M., Mühlematter D., Wicht M., Delacrétaz F., and Schmidt P.M. t(8;9)(p11;q32) in atypical chronic myeloid leukaemia: a new cytogenetic-clinicopathologic association?. Br J Haematol 81 (1992) 307-308
15. Nakayama H., Inamitsu T., Ohga S., Kai T., Suda M., Matsuzaki A., and Ueda K. Chronic myelomonocytic leukaemia with t(8;9)(p11;q34) in childhood: an example of the 8p11 myeloproliferative disorder?. Br J Haematol 92 (1996) 692-695
16. van den Berg H., Kroes W., van der Schoot C.E., Dee R., Pals S.T., Bouts T.H., and Slater R.M. A young child with acquired t(8;9)(p11;q34): additional proof that 8p11 is involved in mixed myeloid/T lymphoid malignancies. Leukemia 10 (1996) 1252-1253
17. Chaffanet M., Popovici C., Leroux D., Jacrot M., Adélaïde J., Dastugue N., Grégoire M.J., Hagemeijer A., Lafage-Pochitaloff M., Birnbaum D., and Pébusque M.J. t(6;8), t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11-12. Oncogene 16 (1998) 945-949
18. Sohal J., Chase A., Mould S., Corcoran M., Oscier D., Iqbal S., Parker S., Welborn J., Harris R.I., Martinelli G., Montefusco V., Sinclair P., Wilkins B.S., van den Berg H., Vanstraelen D., Goldman J.M., and Cross N.C. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer 32 (2001) 155-163
19. Bacher U., Haferlach T., Kern W., Hiddemann W., Schnittger S., and Schoch C. Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 84 (2005) 250-257